drugset / Trial / NCT03745716
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.
Timeline
- Start
- 2019-01-11
- Primary completion
- 2020-11-27
- Completion
- 2022-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | eprenetapopt | Small molecule | — | — |